Page 11234..1020..»

Mallinckrodt to Present New Data from two Studies on Acthar Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at…

Posted: February 27, 2020 at 8:49 pm

STAINES-UPON-THAMES, United Kingdom, Feb. Continue reading

Posted in MS Treatment | Comments Off on Mallinckrodt to Present New Data from two Studies on Acthar Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at…

New Pediatric Multiple Sclerosis Therapies More Effective Than Injectables – Neurology Advisor

Posted: at 8:49 pm

WEST PALM BEACH, FL Using newer disease-modifying therapies for the initial treatment of pediatric multiple sclerosis may be more effective than injectables at controlling disease activity, according to study results presented at the 2020 Forum for Americas Committee for Treatment and Research in Multiple Sclerosis held February 27-29, 2020, in West Palm Beach, Florida. Continue reading

Posted in MS Treatment | Comments Off on New Pediatric Multiple Sclerosis Therapies More Effective Than Injectables – Neurology Advisor

Potential MS Therapy Shows Ability to Protect Neurons, Promote Myelin in Early Tests – Multiple Sclerosis News Today

Posted: at 8:49 pm

Anavex Life Sciences investigational therapy Anavex 2-73 (blarcamesine) showed an ability to protect, repair, and induce the formation of oligodendrocytes the cells that produce the protective myelin layer around neurons in early cell testing, researchers reported. Continue reading

Posted in MS Treatment | Comments Off on Potential MS Therapy Shows Ability to Protect Neurons, Promote Myelin in Early Tests – Multiple Sclerosis News Today

Stopping Tysabri Early Tied to Active PPMS, Smoking and Depression… – Multiple Sclerosis News Today

Posted: at 8:49 pm

The likelihood of discontinuing treatment with Tysabri (natalizumab) is higher among patients with progressive relapsing multiple sclerosis, and those who smoke and are depressed, a study reported. Progressive relapsing MS (PRMS) is now largely considered a subset of primary progressive MS, or PPMS marked by periods of activity (at the time of relapses or new MRI lesions). The study Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population was published in the Multiple SclerosisJournal Experimental, Translational andClinical. Continue reading

Posted in MS Treatment | Comments Off on Stopping Tysabri Early Tied to Active PPMS, Smoking and Depression… – Multiple Sclerosis News Today

Masitinib Slows Disability Progression in PPMS and Non-active… – Multiple Sclerosis News Today

Posted: at 8:49 pm

AB Sciencesmasitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show. Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast cells, microglia, and macrophages. Continue reading

Posted in MS Treatment | Comments Off on Masitinib Slows Disability Progression in PPMS and Non-active… – Multiple Sclerosis News Today

Naturally occurring molecule could improve brain metabolism in patients with MS – News-Medical.net

Posted: at 8:48 pm

N-acetylcysteine (NAC) is a naturally occurring molecule that replenishes antioxidants and shows improved brain metabolism and self-reported improvements in cognitive function in patients with multiple sclerosis, according to a study published in the journal, Frontiers in Neurology. The study found improvements in brain metabolism, particularly in areas that support cognition such as the frontal and temporal lobes in patients with multiple sclerosis. Continue reading

Posted in MS Treatment | Comments Off on Naturally occurring molecule could improve brain metabolism in patients with MS – News-Medical.net

Gilead to Expand Coronavirus Drug Trials to Other Countries – The New York Times

Posted: at 8:48 pm

The drug maker said that in March it would begin two more clinical trials of remdesivir, an experimental antiviral drug, in more nations outside China. The drug maker Gilead Sciences is expanding its clinical trials of the antiviral drug remdesivir as a possible coronavirus treatment into several countries outside China, the company announced on Wednesday. Two new clinical trials of remdesivir are to begin in March, involving approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, Gilead said in a statement Continue reading

Posted in MS Treatment | Comments Off on Gilead to Expand Coronavirus Drug Trials to Other Countries – The New York Times

NeurologyLive Launches Updates to the MRI Protocol and Clinical Guidelines for MS Video Series Along With the Consortium of Multiple Sclerosis Centers…

Posted: at 8:48 pm

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available Continue reading

Posted in MS Treatment | Comments Off on NeurologyLive Launches Updates to the MRI Protocol and Clinical Guidelines for MS Video Series Along With the Consortium of Multiple Sclerosis Centers…

TG Therapeutics Edges Closer To Commercialization And Potential Share Price Gain – Seeking Alpha

Posted: at 8:48 pm

Investment Thesis I last posted about TG Therapeutics (TGTX) in November last year after the company published long-awaited positive trial data concerning flagship drugs umbralisib and ublituximab, which caused a small uptick in the share price from ~$5 to ~$9. I felt that TG was edging closer to commercialising its first drug and recommended its stock as a speculative investment - since then the share price has continued to grow and has reached $16 at the time of posting this update on further positive news flow. The next few months promise to be a critical period for the company. Continue reading

Posted in MS Treatment | Comments Off on TG Therapeutics Edges Closer To Commercialization And Potential Share Price Gain – Seeking Alpha

Study aims to find ‘more tailored treatment’ for patients with Multiple Sclerosis – Nottinghamshire Live

Posted: at 8:48 pm

A study being carried out in Nottingham aims to pave the way for more personalised treatments for patients with Multiple Sclerosis (MS). Each day, around 14 people are diagnosed with the debilitating disease that can leave people struggling to walk, feeing tired and experiencing muscle weakness or spasms. Continue reading

Posted in MS Treatment | Comments Off on Study aims to find ‘more tailored treatment’ for patients with Multiple Sclerosis – Nottinghamshire Live

Page 11234..1020..»